What's New in Insulin?

Friday, September 11, 2015; 5:307:45 PM EST
Intercontinental Miami Hotel, Grand Ballroom

This course is a live CME-certified ancillary symposium presented at the 67th Clinical Endocrinology Update (CEU) Meeting, held in Miami, Florida, September 1012, 2015. CEU 2015 ancillary symposia are developed through the Endocrine Society's Special Programs Committee (SPC).

This activity is supported by an educational grant from Novo Nordisk Inc.


Welcome, Introduction and Presentation of ARS
Program Director: Carol H. Wysham, MD, Rockwood Clinic

New Basal Insulins
Carol H. Wysham, MD, Rockwood Clinic

New Combinations
Jack L. Leahy, MD

New Horizons in Insulin Therapy
Mark R. Burge

ARS Review and Panel Discussion

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Select and optimize the most appropriate basal insulin strategy taking recent advancements into consideration
  • Apply therapies in combination with insulin and discuss emerging options to optimize treatment of patients with diabetes
  • Discuss emerging insulin formulations and delivery devices

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Intercontinental Miami Hotel
Miami, FL
United States

Carol H. Wysham, MD – Program Director
Clinical Associate Professor of Medicine
University of Washington School of Medicine
Section Head, Department of Diabetes and Endocrinology, Rockwood Clinic
Spokane, Washington

Jack L. Leahy, MD
Professor of Medicine
Chief of Endocrinology, Diabetes and Metabolism
University of Vermont
Colchester, Vermont

Mark R. Burge, MD
Professor of Medicine
Deputy Director, University of New Mexico
Clinical & Translational Science Center
Albuquerque, New Mexico


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Carol Wysham, MD (Chair): Consultant and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Janssen Pharmaceuticals, Sanofi-Aventis; Consultant, Dance Pharmaceuticals; Speaker, Novo Nordisk
Jack L Leahy, MD: Advisory Board Member, Janssen, Merck, Novo Nordisk, Roche, Sanofi
Mark Burge, MD: Research Grant Support, Grifols Inc, Sanofi, VisionQuest LLC

The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships:
Irl B Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation